SCHEMBL3451933

SCHEMBL3451933

COC(=O)CC(=O)c1cncc(-c2cnc(Nc3ccc(F)c(Cl)c3)nc2N2CCOCC2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ JAK2 O60674 2/20 0.42
▸ FLT3 P36888 1/20 0.42
▸ SYK P43405 3/20 0.41
▸ MTOR P42345 3/20 0.41
▸ BCL6 P41182 1/20 0.41
▸ MAPK9 P45984 1/20 0.40
▸ MAPK10 P53779 1/20 0.40
▸ LRRK2 Q5S007 3/20 0.40
▸ BTK Q06187 1/20 0.40
▸ PIK3CA P42336 2/20 0.40
▸ PIK3CD O00329 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ AKT1 P31749 1/20 0.40
▸ PIK3CB P42338 1/20 0.40
▸ PIK3CG P48736 1/20 0.40
▸ EGFR P00533 1/20 0.40
▸ AURKA O14965 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3450200 0.88 SMN1; SMN2 (0.44) NPC1RAB9ASMN1; SMN2JAK2FLT3
SCHEMBL3448122 0.88 P2RY12 (0.46) NPC1RAB9ASMN1; SMN2JAK2FLT3
SCHEMBL13310863 0.82 NPC1 (0.49) NPC1RAB9ASMN1; SMN2SYKBCL6
SCHEMBL3448877 0.81 JAK2 (0.45) NPC1RAB9ASMN1; SMN2JAK2MTOR
SCHEMBL13311435 0.81 NPC1 (0.51) NPC1RAB9ASMN1; SMN2JAK2SYK
SCHEMBL3348458 0.81 NPC1 (0.49) NPC1RAB9ASMN1; SMN2JAK2FLT3
SCHEMBL3447594 0.81 JAK2 (0.45) NPC1RAB9ASMN1; SMN2JAK2FLT3
SCHEMBL13312654 0.81 PAK1 (0.46) NPC1RAB9ASMN1; SMN2JAK2SYK
SCHEMBL3451095 0.81 MEN1 (0.49) NPC1RAB9ASMN1; SMN2JAK2FLT3
SCHEMBL3450175 0.81 ABL1 (0.36) SYKEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 — — US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 — — US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 — — US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD NPC1 603/4885RAB9A 2449/4885SMN1; SMN2 3328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback